bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

NATIONAL HARBOR, Md. — Individuals pardoned by President Trump over their involvement in the Jan. 6 Capitol riot are off-stage stars at the Conservative Political Action Conference (CPAC ...

bluebird bio stock opened at $4.08 on Friday. The firm has a market capitalization of $39.66 million, a P/E ratio of -0.11 and a beta of 0.68. The stock has a fifty day moving average price of $7. ...

The Somerville gene therapy company was once among the highest-profile biotechs in the Boston area, but now has agreed to be taken private for a small fraction of the amount at which it was once ...

For a full version of this story, visit STAT. Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $ ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ: BLUE) to Carlyle Group and SK Capital Partners, LP is fair to bluebird shareholders.

Jan Molby has expressed his bewilderment at Trent Alexander-Arnold's recent admission that winning the Ballon d'Or would be more meaningful to him than clinching the World Cup. The Liverpool full ...

Bluebird’s lead CAR-T cancer cell therapy idecabtagene vicleucel (ide-cel) was last year hit with an FDA refuse-to-file letter, which required additional data on chemistry, manufacturing and ...

As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises "substantial doubt" about its ability to continue as a going concern.

Bluebird bio, a pioneering gene therapy developer that in recent years has struggled to stay afloat, has agreed to be acquired and taken private in a deal with investment firms Carlyle Group and SK ...